Clinical Trial Update: An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia [Phase 2]

View source ↗

Summary

An extension Phase 2 trial evaluating the safety and anti-leukemic effects of imatinib mesylate in adults with Ph+ leukemias has completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Philadelphia Positive Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-07-22